NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis $0.0097 0.00 (-22.40%) As of 02:18 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About ProPhase Labs Stock (NASDAQ:PRPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProPhase Labs alerts:Sign Up Key Stats Today's Range$0.0090▼$0.012050-Day Range$0.01▼$0.0752-Week Range$0.01▼$6.66Volume217,623 shsAverage Volume216,827 shsMarket Capitalization$175.76 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview ProPhase Labs, Inc. is a diversified health and wellness company focused on diagnostics, genomics, consumer healthcare products and related biopharmaceutical opportunities. The company operates through businesses that develop and commercialize products and services intended to support disease detection, personalized health information and consumer wellness. Its consumer healthcare operations include Cold-EEZE zinc-based products, which are marketed in forms such as lozenges and oral sprays for common-cold symptom support. ProPhase Labs has also been involved in laboratory testing and diagnostic services through its ProPhase Diagnostics business, including molecular testing capabilities developed during the COVID-19 pandemic. The company expanded into genomics through its acquisition of Nebula Genomics, a business focused on whole-genome sequencing and enabling individuals to access and control their genetic data. ProPhase Labs serves customers primarily in the United States, with certain consumer products distributed through retail and other commercial channels. Ted Karkus serves as the company’s chairman and chief executive officer. The company was formerly known as The Quigley Corporation before adopting the ProPhase Labs name.AI Generated. May Contain Errors. Read More ProPhase Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScorePRPH MarketRank™: ProPhase Labs scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingProPhase Labs has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageProPhase Labs has received no research coverage in the past 90 days.Read more about ProPhase Labs' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ProPhase Labs are expected to grow in the coming year, from ($1.27) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ProPhase Labs' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PRPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.18 News SentimentProPhase Labs has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ProPhase Labs this week, compared to 1 article on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders9.60% of the stock of ProPhase Labs is held by insiders.Percentage Held by Institutions9.45% of the stock of ProPhase Labs is held by institutions.Read more about ProPhase Labs' insider trading history. Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRPH Stock News HeadlinesProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Below Two Hundred Day Moving Average - Time to Sell?September 22 at 3:41 AM | americanbankingnews.comAnalyzing ProPhase Labs (NASDAQ:PRPH) & Nutriband (NASDAQ:NTRB)September 21 at 7:45 AM | americanbankingnews.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.September 24 at 1:00 AM | Stansberry Research (Ad)ProPhase Labs Delays Quarterly SEC FilingAugust 14, 2026 | tipranks.comProPhase Labs Inc.July 16, 2026 | marketwatch.comProPhase Labs Announces Immediate Resignation of Board MemberJune 25, 2026 | theglobeandmail.comProPhase Labs Delays Quarterly Financial FilingMay 15, 2026 | tipranks.comProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections PlatformApril 15, 2026 | globenewswire.comSee More Headlines PRPH Stock Analysis - Frequently Asked Questions How have PRPH shares performed this year? ProPhase Labs' stock was trading at $0.4475 at the beginning of the year. Since then, PRPH stock has decreased by 97.8% and is now trading at $0.0097. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) issued its quarterly earnings results on Wednesday, November, 19th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.10) by $0.50. The company had revenue of $0.88 million for the quarter, compared to the consensus estimate of $5.69 million. ProPhase Labs had a negative trailing twelve-month return on equity of 482.05% and a negative net margin of 825.01%. Read the conference call transcript. When did ProPhase Labs' stock split? Shares of ProPhase Labs reverse split on the morning of Monday, December 22nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET). Company Calendar Last Earnings11/19/2025Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PRPH's financial health is in the Red zone, according to TradeSmith. PRPH has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRPH CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees130Year Founded1981Profitability EPS (Trailing Twelve Months)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.36 million Net Margins-825.01% Pretax Margin-680.20% Return on Equity-482.05% Return on Assets-88.90% Debt Debt-to-Equity Ratio0.14 Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$5.06 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.00Miscellaneous Outstanding Shares18,120,000Free Float5,444,000Market Cap$175.76 thousand OptionableNo Data Beta0.06 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:PRPH) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
